Janssen to start phase III trial of daratumumab in multiple myeloma in Q4 2014
The phase III trial will compare daratumumab in combination with bortezomib, melphalan and prednisone to bortezomib, melphalan and prednisone alone as front line treatment for patients who are
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.